Royalty Pharma (RPRX) announced a research and development co-funding agreement with Johnson & Johnson (JNJ) for a total of $500M in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. JNJ-4804 is a novel co-antibody therapy that blocks the complementary interleukin-23 and tumor necrosis factor pathways, delivering synergistic effects on the pathogenesis of chronic immune-mediated diseases.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Zymeworks price target raised to $48 from $33 at Evercore ISI
- Royalty Pharma appoints Kenneth Sun as Senior Vice President, Head of Asia
- Zymeworks, Royalty Pharma enter $250M royalty-backed note financing
- Royalty Pharma price target raised to $50 from $45 at TD Cowen
- The Week That Was, The Week Ahead: Macro and Markets, Feb. 15